Mab Immunotherapies For Myeloid Leukemia Patients With Germline Or Somatic RUNX1 Mutations.
Funder
National Health and Medical Research Council
Funding Amount
$766,995.00
Summary
This proposal presents preliminary evidence and proposes to confirm that 2 cell surface molecules, CD11a (ITGAL) and IL3RA (CD123) are direct (probably repression) targets of RUNX1 in HSCs, and are dysregulated in RUNX1 mutated AML. Monoclonal antibody therapies that target these two surface molecules have already passed different clinical trial phases for different diseases. We plan to show these antibodies are effective in RUNX1 positive AML in preclinical models and then clinical trials.
Industrial Transformation Training Centres - Grant ID: IC170100016
Funder
Australian Research Council
Funding Amount
$3,123,492.00
Summary
ARC Training Centre for Personalised Therapeutics Technologies. The ARC Training Centre for Personalised Therapeutics Technologies aims to create and develop the skills and technology to benefit from the transformative impacts that cell/organ-on-a-chip technology will have on the medtech/pharma industries. By combining microfluidics-based/real-time technologies with personalised medicine the Training Centre will provide industry growth opportunities through improved screening of potential therap ....ARC Training Centre for Personalised Therapeutics Technologies. The ARC Training Centre for Personalised Therapeutics Technologies aims to create and develop the skills and technology to benefit from the transformative impacts that cell/organ-on-a-chip technology will have on the medtech/pharma industries. By combining microfluidics-based/real-time technologies with personalised medicine the Training Centre will provide industry growth opportunities through improved screening of potential therapeutics. The use of an individual patient’s cellular and molecular research findings will ultimately enable personalised diagnostic and therapeutic decisions.Read moreRead less
Unveiling the epigenome dynamics through the pluripotency continuum. This project aims to utilise stem cells and genomics based technologies, in combination with new computational algorithms to dissect the fundamental molecular events that drive the first steps during development. The project is expected to unveil the basic mechanisms underpinning how genes driving the developmental master plan are controlled in cells that have the capacity to give rise to the whole organism and placenta. The kn ....Unveiling the epigenome dynamics through the pluripotency continuum. This project aims to utilise stem cells and genomics based technologies, in combination with new computational algorithms to dissect the fundamental molecular events that drive the first steps during development. The project is expected to unveil the basic mechanisms underpinning how genes driving the developmental master plan are controlled in cells that have the capacity to give rise to the whole organism and placenta. The knowledge gained from this work will inform and guide future novel approaches, such as in assisted reproductive technologies or regenerative medicine.Read moreRead less
Glucose is a critical fuel for living organisms and its presence in the gut triggers nerves that slow stomach emptying. However, little is known of how glucose is actually detected in the gut. We have established that sweet taste molecules of the tongue are also present in the gut, where they may detect glucose. This research will measure the expression and function of these molecules in the gut of humans and mice, and reveal key information on their potential as targets in health and disease.
Industrial Transformation Training Centres - Grant ID: IC190100026
Funder
Australian Research Council
Funding Amount
$4,969,663.00
Summary
ARC Training Centre for Cell and Tissue Engineering Technologies. The ARC Training Centre for Cell and Tissue Engineering Technologies aims to provide training to create a highly skilled workforce for the tissue engineering and regenerative medicine sector and to enhance research performance and innovation in Australia through fundamental and applied research carried out in industry-led PhD projects. The research aims to address major aspects of the manufacturing and commercialisation pathway an ....ARC Training Centre for Cell and Tissue Engineering Technologies. The ARC Training Centre for Cell and Tissue Engineering Technologies aims to provide training to create a highly skilled workforce for the tissue engineering and regenerative medicine sector and to enhance research performance and innovation in Australia through fundamental and applied research carried out in industry-led PhD projects. The research aims to address major aspects of the manufacturing and commercialisation pathway and barriers faced by the sector, namely improving process efficiencies, enabling early-stage scale-up (cell/tissue) and development of the sector's supply chain. The knowledge created and research undertaken would help to accelerate commercialisation in regenerative medicine, tissue engineering and cell therapies.Read moreRead less
Brain Repair Following Stroke: The Role Of Npas4, A Neural-specific Transcription Factor
Funder
National Health and Medical Research Council
Funding Amount
$611,053.00
Summary
Stroke is the #1 cause of adult disability in Australia and #2 cause of death. About 60,000 Australians suffer a stroke each year while about 250,000 live with the disabilities of stroke, costing over $2B/year. The Queen Elizabeth Hospital and University of Adelaide will study why the Npas4 gene switches on after stroke and the role it plays in brain repair. Future health benefits may be tests to help improve stroke outcome in patients and therapy to decrease loss of brain cells after stroke.
Understanding How GATA2 Controls Lymphatic Vessel Valve Development
Funder
National Health and Medical Research Council
Funding Amount
$697,942.00
Summary
Mutations in the GATA2 gene cause human lymphoedema as a result of the crucial role that GATA2 plays in controlling the expression of genes important for building functional lymphatic vessels. Here we aim to gain a complete picture of the cellular and molecular events that are controlled by GATA2 in lymphatic vessels and in particular, in lymphatic vessel valves.
Deciphering The Transcriptional Program That Instructs Lymphatic Endothelial Cell Fate.
Funder
National Health and Medical Research Council
Funding Amount
$541,950.00
Summary
Lymphatic vessels are essential to maintain fluid balance in most tissues of the human body. Further the lymphatic vasculature plays a central role during cancer and contributes to tumour metastasis. Despite this integral function in health and disease little is known about the molecular programs that coordinate gene expression to build a functional vasculature. This research project will address this gap in our knowledge and will open up new therapeutic avenues for lymphatic vascular disorders
Transplantation of pancreatic islets is the only cure for type 1 diabetes (T1D). Unfortunately, many of the transplanted islet cells die quickly due to an inadequate supply of blood. Herein, we investigate a novel cell surface protein for its role in islet and blood vessel survival and function. Furthermore, we use nanotechnology to provide said protein to the islet cells during transplantation for increased survival and function. Ultimately, this work may cure more patients with diabetes.
Histone Demethylase KDM6A Is A Novel Target For Treating Craniosynostosis In Children With Saethre-Chotzen Syndrome
Funder
National Health and Medical Research Council
Funding Amount
$548,854.00
Summary
Children with Saethre-Chotzen syndrome exhibit premature fused coronal sutures, and other skull/ skeletal malformations. Surgical intervention is the only treatment option to ensure optimal cognitive and skeletal development. Our studies have identified a candidate molecular pathway that regulates bone formation by cranial bone cells from these patients. Targeting this key molecular regulator with chemical inhibitors will help prevent the premature fusion of cranial sutures.